Replimune Group

Replimune Group is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors.
  • TickerREPL
  • ISINUS76029N1063
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Ashiq Mubarack ...
  • Robert Driscoll

Fiscal Q1 Financials; First Look at RP1 Ahead

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • Robert Driscoll

Fiscal Q1 Financials; First Look at RP1 Ahead

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ValuEngine Rating and Forecast Report for REPL

ResearchPool Subscriptions

Get the most out of your insights

Get in touch